Invasive Fungal Infection Clinical Trial
Official title:
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection
Invasive fungal infections (IFI) remain the major cause of death among neutropenic patients
receiving chemotherapy for leukemia, or submitted to stem cell transplantation. Patients
with a history of invasive fungal infection (IFI) are at high risk of developing relapse and
fatal complications.
Prompt intensive antifungal therapy, have improved responses and survival, allowing an
increase of antifungal treatments, including secondary antifungal prophylaxis.
Few studies have addressed the role of previous IFI in the feasibility of stem cell
transplant, or the secondary prophylaxis with antifungal drugs in preventing recurrence of
infection after transplantation. However, given the lack of prospective studies, the role of
secondary antifungal prophylaxis remains unclear.
Itraconazole is a wide-spectrum triazole antifungal agent active against Candida albicans,
non-albicans, Aspergillus spp., Blastomyces dermatitidis, Blastomyces coccidioides,
Cryptococcus neoformans, Sporothrix schenkii, Paracoccidioides brasiliensis, Histoplasma
spp. and various kinds of yeast fungi and mycetes.
The role of itraconazole IFI prophylaxis treatment has been proved by many interventional
studies. In this prospective, multicentric study of secondary prophylaxis, itraconazole will
be given at standard dose to patients undergoing allogeneic stem cell transplantation or
chemotherapy with prior invasive fungal infection, to assess the efficacy and safety of
itraconazole secondary prophylaxis.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01888458 -
Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)
|
Phase 2 | |
| Completed |
NCT00412893 -
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
|
Phase 3 | |
| Completed |
NCT03066011 -
Registry of Patients Treated With Systemic Mold-Active Triazoles
|
||
| Completed |
NCT04004078 -
An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
|
||
| Completed |
NCT01576653 -
Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL
|
N/A | |
| Enrolling by invitation |
NCT02510053 -
Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit
|
N/A | |
| Recruiting |
NCT06137690 -
Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
|
||
| Completed |
NCT01783379 -
Pharmacokinetics of Micafungin in Patients Intensive Care Unit
|
||
| Completed |
NCT01533558 -
Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
|
||
| Recruiting |
NCT03149562 -
Association of Plasma Transfusions and Invasive Fungal Infection
|
||
| Recruiting |
NCT04665037 -
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
|
Phase 2 | |
| Withdrawn |
NCT01185405 -
Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients
|
N/A | |
| Terminated |
NCT01148160 -
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
|
N/A | |
| Completed |
NCT00893555 -
Pharmacologic Optimization of Voriconazole
|
Phase 3 | |
| Unknown status |
NCT00460330 -
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT
|
N/A | |
| Completed |
NCT02823132 -
Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia
|
N/A |